Bionano Genomics (BNGO) Q4 2025: 47% CPT Reimbursement Increase Catalyzes Shift to Profitable Consumable Growth
Bionano Genomics executed a strategic pivot focusing on high-volume routine users, resulting in stable consumable sales despite overall revenue decline. The 47% increase in CPT reimbursement rates for hematologic malignancies underpins a strong 2026 growth outlook. Operational efficiencies drove a 1200 basis point gross margin expansion, signaling improved scalability and path to profitability.
Summary
- Consumable-Driven Growth Focus: Emphasis on routine users is stabilizing consumable revenue amid system sales variability.
- Reimbursement Catalyst: Significant CPT code payment increase supports accelerated adoption and utilization.
- Operational Transformation: Cost reductions and margin expansion position Bionano for sustainable profitability.
Business Overview
Bionano Genomics is a provider of genome analysis solutions leveraging optical genome mapping (OGM) technology to enable researchers and clinicians to detect structural variants in genomic DNA. The company generates revenue primarily through sales of OGM instruments, consumables including nanochannel array flowcells, and software licenses. Its major segments include instrument sales, consumables and software, and diagnostic services, with a strategic shift toward consumables and software to drive recurring revenue.
Performance Analysis
In the fourth quarter of 2025, Bionano reported $8.0 million in revenue, a slight 3% decline year-over-year, with consumables and software revenue down 1%. The company sold 7,554 flowcells, a 6% decrease influenced by supply constraints from a manufacturing partner late in the quarter. The installed base of OGM systems grew 4% to 387 units, reflecting ongoing customer adoption. For the full year, revenue declined 7% to $28.5 million, but excluding discontinued clinical services, core revenue fell only 2%, and consumables plus software revenue grew 7% to $20.4 million, representing 71% of total revenue, up from 62% in 2024.
Bionano significantly improved profitability metrics, with non-GAAP gross margin rising to 43% in Q4 and 47% for the full year, a 1200 basis point increase over 2024 despite lower revenue. Operating expenses were reduced by 22% in Q4 and 55% for the full year on a GAAP basis, reflecting successful cost structure transformation including headcount reductions and efficiency initiatives. Cash and equivalents stood at $29.6 million at year-end, supporting a runway into 2027. These results underscore the company’s effective transition toward a more predictable, consumables-driven revenue model with improved margin profiles.
- Revenue Mix Shift: Consumables and software now constitute the majority of revenue, reflecting a strategic pivot from instrument sales.
- Supply Chain Impact: Manufacturing delays constrained flowcell sales late in Q4, creating a backlog expected to drive future sales.
- Installed Base Growth: System installations exceeded guidance, with 32 new OGM systems added in 2025, supporting long-term consumable demand.
This financial and operational progress lays a foundation for sustainable growth, leveraging routine users to drive higher consumable utilization and improved profitability.
Executive Commentary
"Our routine users of optical genome mapping and VIA software remain the foundation of our revenue and gross margins, and we are pleased to see continued growth in utilization among this core customer base."
Erik Holmlin, Chief Executive Officer
"Our non-GAAP gross margins have now expanded from 22% in the first quarter of 2023 to 43% in the fourth quarter of 2025. And while quarterly non-GAAP operating expenses fell from roughly $34 million to now under $10 million over that same period."
Mark Adamczyk, Vice President of Accounting and Principal Accounting Officer
Strategic Positioning
1. Concentration on Routine Users to Drive Consumable Revenue
Bionano identified approximately 130 routine use customers who operate 45% of the installed OGM systems and generate 83% of consumable revenue. These customers have validated protocols and institutional funding, providing a stable and profitable revenue base. The company is prioritizing selective new customer acquisition within this segment to expand consumable sales and deepen adoption.
2. Menu Expansion and Software Integration to Enhance Utilization
Advancements in VIA software and the ionic system automate and simplify workflows, enabling broader application of OGM beyond hematologic malignancies into constitutional genetic disorders. The release of software upgrades such as VS 7.2 and SOLVE 3.8.3 improves analysis accuracy and throughput, supporting increased sample processing and expanding the addressable market.
3. Reimbursement and Guideline Support as Adoption Catalysts
The 47% increase in the 2026 Clinical Lab Fee Schedule payment for the Category I CPT code related to hematologic malignancies, alongside a newly established CPT code for constitutional genetic disorders, provides critical reimbursement infrastructure. This fosters broader clinical adoption and supports inclusion in professional society guidelines, accelerating market penetration.
4. Operational Efficiency and Cost Structure Transformation
Bionano’s aggressive cost reduction initiatives, including headcount cuts and process improvements, have halved operating expenses since 2023. Gross margin expansion from 22% to 43% in two years reflects improved product mix favoring consumables and enhanced operational scalability, positioning the company toward EBITDA breakeven.
5. Industry Leadership and Community Engagement
Hosting the Bionano Symposium 2026 with over 1,250 registrants and showcasing advances in OGM at scale demonstrates leadership in the genomics community. Collaborations with academic centers and national labs validate the technology’s scalability and cost advantages compared to long-read sequencing, reinforcing Bionano’s competitive positioning.
Key Considerations
Bionano’s strategic shift toward a consumable-driven revenue model underpinned by routine users is central to its path to sustainable growth and profitability. The company’s ability to convert routine users to validated protocol adopters and expand their consumable usage will be key growth drivers. Operational improvements have materially enhanced margins and reduced cash burn, extending the runway into 2027.
Key Considerations:
- Consumable Revenue Stability: Despite system sales fluctuations, consumables show resilience and growth potential.
- Supply Chain Constraints: Temporary manufacturing delays may impact near-term sales but create backlog for future quarters.
- Reimbursement Expansion: Higher CPT code payments are expected to accelerate clinical adoption and utilization.
- Customer Base Focus: Routine users represent a concentrated and profitable segment driving majority consumable revenue.
- Cost Structure Improvements: Significant expense reductions support margin expansion and financial sustainability.
Risks
Bionano faces risks from supply chain disruptions, which constrained consumable sales late in 2025 and could affect near-term revenue. The company’s dependence on a concentrated routine user base means that adoption rates and protocol validation progress are critical. Competitive pressures from alternative genomic technologies and potential reimbursement changes also pose risks to growth trajectory.
Forward Outlook
For the first quarter of 2026, Bionano guided revenue between $6.5 million and $6.7 million, implying flat to 3% growth year-over-year. Full-year 2026 revenue guidance ranges from $30 million to $33 million, representing 5% to 16% growth over 2025. Management expects revenue growth to be driven by increased consumable sales at existing customers and new system placements, supported by easing supply constraints and enhanced reimbursement.
Management highlighted factors influencing guidance:
- Continued expansion of consumable utilization among routine users.
- Positive impact of the 47% CPT reimbursement increase effective January 2026.
Takeaways
Bionano’s transition to a consumable-centric model backed by a stable routine user base and improved reimbursement positions the company for sustainable revenue growth and margin expansion. Operational efficiencies achieved through cost reductions and product mix shifts enhance financial resilience. Investors should monitor the pace of routine user protocol validation and consumable adoption as key growth indicators.
- Revenue Model Evolution: The shift from instrument sales to consumable and software revenue provides a more predictable and profitable foundation.
- Reimbursement as Growth Lever: The significant increase in CPT code payments is a major catalyst for accelerating clinical adoption.
- Execution Focus: Maintaining supply chain stability and expanding routine user engagement will be critical to achieving 2026 guidance.
Conclusion
Bionano Genomics demonstrated strategic discipline in 2025 by focusing on high-value routine users and enhancing operational efficiency, resulting in improved margins despite revenue headwinds. The 2026 outlook, supported by favorable reimbursement changes and a growing installed base, suggests a trajectory toward profitable growth and market leadership in optical genome mapping.
Industry Read-Through
Bionano’s experience underscores the importance of reimbursement infrastructure in driving adoption of advanced genomic technologies. The company’s focus on consumable-driven revenue models and operational scalability offers a blueprint for other genomics firms navigating the transition from capital equipment sales to recurring revenue streams. Supply chain resilience remains a critical factor for the broader industry, as manufacturing constraints can materially impact consumable availability and growth. The growing acceptance of OGM as a cost-effective alternative to long-read sequencing highlights evolving competitive dynamics in genomic analysis.